2021 ASH Annual Meeting & Exposition
The chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (liso-cel) significantly improved event-free ...
According to results from the phase III BELINDA trial, patients with relapsed/refractory aggressive B-cell non-Hodgkin ...
The chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel) demonstrated significant and ...
At more than three years of follow-up, most patients with chronic lymphocytic leukemia (CLL) who were treated with a ...
According to the presentation at the 2021 American Society of Hematology Annual Meeting, real-world patients with ...
Pivotal trials that supported Food and Drug Administration (FDA) approval of chimeric antigen receptor (CAR) T-cell ...
Treatment with the investigational injectable hepcidin mimetic rusfertide effectively controlled levels of hematocrit ...
According to results from a phase I/II study, more than 90% of older and high-risk patients with newly diagnosed acute ...
First-line treatment with the autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy axicabtagene ...
In a single-arm phase I/II study, infusion with CT103A, a novel fully human B-cell maturation antigen (BCMA)-targeted ...
Chimeric antigen receptor (CAR) T-cell therapy is a potentially life-saving option for patients with hematologic ...
According to results from the phase III BELINDA trial, patients with relapsed/refractory aggressive B-cell non-Hodgkin ...
According to findings from the REGARDS trial, peripheral blood cytopenias may be associated with a higher risk of ...
According to a poster presentation at the 2021 American Society of Hematology, prescribing chemotherapy is not a ...
According to results from the ASCEMBL trial, asciminib was superior to bosutinib in inducing major molecular responses ...
For patients with chronic myeloid leukemia (CML), treatment with tyrosine kinase inhibitors (TKIs) has increased the ...
According to three-year follow-up data from the ASCEND trial, patients with relapsed/refractory chronic lymphocytic ...
Zanubrutinib Plus Venetoclax Well-Tolerated, Effective as First-Line Therapy for CLL/SLL With Del17p
Preliminary data from a nonrandomized arm of the SEQUOIA trial, presented at the 2021 Annual Meeting of the American ...Although individuals older than 80 years make up more than 20% of cases of chronic lymphocytic leukemia (CLL), this ...
According to a study presented at the 2021 American Society of Hematology Annual Meeting, frontline treatment with ...
According to a study that reviewed response and survival outcomes in Waldenström macroglobulinemia (WM) patients who ...
The bispecific antibody teclistamab displayed a manageable safety profile at the recommended phase II dose and continued ...
Pivotal trials that supported Food and Drug Administration (FDA) approval of chimeric antigen receptor (CAR) T-cell ...
Preliminary data from a nonrandomized arm of the SEQUOIA trial, presented at the 2021 Annual Meeting of the American ...
Although individuals older than 80 years make up more than 20% of cases of chronic lymphocytic leukemia (CLL), this ...
Second-line therapy comprising standard rituximab plus bendamustine and bortezomib was effective and well-tolerated as a ...
A mixed-method study of Dutch patients, presented at the 63rd American Society of Hematology Annual Meeting & ...
At the 2021 American Society of Hematology (ASH) Annual Meeting, researchers presented long-term follow-up data from a ...
Patients with mantle cell lymphoma (MCL), Waldenström macroglobulinemia (WM), marginal zone lymphoma (MZL), and chronic ...
Adoptive immunotherapy with CD4+/CD25/+FOXP3+ regulatory T cells (Tregs) and conventional T cells (Tcons) has been used ...
Mosunetuzumab was safe and efficacious for patients with heavily pretreated relapsed and/or refractory B-cell ...
A study that reviewed response and survival outcomes in Waldenström macroglobulinemia (WM) patients who underwent ...
According to extended follow-up from the GRIFFIN trial, the combination of daratumumab and lenalidomide, bortezomib, and ...
Results from the phase II IDIOME trial suggest that ivosidenib, a small-molecule mutant IDH1 inhibitor, showed good ...
For patients with myelodysplastic syndromes (MDS), an updated International Prognosis Scoring System (IPSS) that ...
TP53 is the most commonly mutated gene in human cancer. Presence of “multi-hit” TP53 mutations is associated with ...
According to research presented during the 2021 ASH Annual Meeting, induction and consolidation therapy comprising ...
In an open-label, multicenter study presented at the 2021 ASH Annual Meeting, the combination of sabatolimab and ...
Patients with hematologic malignancies who may require blood transfusions are often unable to enroll in hospice care ...
The combination of magrolimab with venetoclax and azacitidine was considered safe and highly effective in older and ...
At the 2021 American Society of Hematology Annual Meeting and Exposition, Fabio Efficace, PhD, and a team of researchers ...
Black Americans were severely under-represented in clinical trials that supported FDA approvals of chimeric antigen ...
According to findings presented at the 2021 ASH Annual Meeting, the combination of daratumumab, carfilzomib, ...
Findings from phase II of the phase I/II MajesTEC-1 study on teclistamab were presented for the first time at the 2021 ...
In a study conducted presented at the 2021 American Society of Hematology Annual Meeting, researchers led by Aisha S. ...
The treatment combination of azacitidine with venetoclax and magrolimab was safe and highly effective in older and ...
Patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (NHL) who received second-line treatment with ...
Patients with hematologic malignancies who may require blood transfusions may not be able to enroll in hospice care ...
Updated results from a real-world analysis confirm that ruxolitinib is an effective treatment option for patients with ...
According to updated data from the phase I/II BRUIN study, presented at the 2021 American Society of Hematology Annual ...
Advertisement
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.